epilepsy

Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91(3):483-8. DOI: 10.1038/clpt.2011.251. PubMed PMID: 22278332.

The antiepileptic drug carbamazepine can cause adrenal insufficiency in patients under hormone replacement therapy for congenital adrenal hyperplasia.

Gullo D, Gelsomino R, Marturano I, Restivo D, Arpi ML, Leonardi D, et al. The antiepileptic drug carbamazepine can cause adrenal insufficiency in patients under hormone replacement therapy for congenital adrenal hyperplasia. Hormones (athens). 2013;12(3):470-1. PubMed PMID: 24121390.

Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52(12):1045-61. DOI: 10.1007/s40262-013-0088-z. PubMed PMID: 23794036.

The clinical impact of pharmacogenetics on the treatment of epilepsy.

Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50(1):1-23. DOI: 10.1111/j.1528-1167.2008.01716.x. PubMed PMID: 18627414.

Effectiveness of first antiepileptic drug.

Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42(10):1255-60. PubMed PMID: 11737159.

Pharmacogenomics and epilepsy: the road ahead.

Cavalleri GL, McCormack M, Alhusaini S, Chaila E, Delanty N. Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics. 2011;12(10):1429-47. DOI: 10.2217/pgs.11.85. PubMed PMID: 22008048.

Personalized medicine approaches in epilepsy.

Walker LE, Mirza N, Yip VLM, Marson AG, Pirmohamed M. Personalized medicine approaches in epilepsy. J Intern Med. 2015;277(2):218-34. DOI: 10.1111/joim.12322. PubMed PMID: 25338670.

Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.

Ebid A-HIM, Ahmed MMM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit. 2007;29(3):305-12. DOI: 10.1097/FTD.0b013e318067ce90. PubMed PMID: 17529887.

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005;102(15):5507-12. DOI: 10.1073/pnas.0407346102. PubMed PMID: 15805193.

Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients.

Grover S, Bala K, Sharma S, Gourie-Devi M, Baghel R, Kaur H, et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 2010;92(9):1207-12. DOI: 10.1016/j.biochi.2010.04.008. PubMed PMID: 20417680.